Cytokinetics
CYTK
95 hedge funds and large institutions have $254M invested in Cytokinetics in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 40 reducing their positions, and 21 closing their positions.
47% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $919K
34% more capital invested
Capital invested by funds: $189M → $254M (+$64.6M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less funds holding
Funds holding: 109 → 95 (-14)
40% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 40
62% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$10.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.75M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.32M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$4.13M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.3M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.54M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.16M |
| 4 |
MCM
Matarin Capital Management
New York
|
-$1.86M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.84M |
CYTK Hedge Fund Activity: Q2 2016 in Review
95 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2016, worth a combined $254M — up 34% from $189M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CYTK and 8 opened new positions — a net loss of 13 holders — while 40 trimmed existing stakes and 24 added.
The largest buyer was Wasatch Advisors, adding an estimated $10.4M. The largest seller was Acadian Asset Management, cutting an estimated $7.3M.
- 95 institutional investors held Cytokinetics (CYTK) as of Q2 2016, down from 109 in Q1 2016.
- Funds reported $254M of Cytokinetics stock for Q2 2016, up 34% quarter-over-quarter.
- 8 funds opened new Cytokinetics positions in Q2 2016 and 21 closed out, a net change of -13 holders.
- The largest Cytokinetics buyer in Q2 2016 was Wasatch Advisors, an estimated $10.4M added.
- The largest Cytokinetics seller in Q2 2016 was Acadian Asset Management, an estimated $7.3M sold.
Based on aggregated 13F filings for Q2 2016.